Subscription price determined and exercise pe...

Precise Biometrics sets SEK 0.47 subscription price for 2026 warrants, exercise now open.

What the company is saying

Precise Biometrics AB has formally set the subscription price for its series 2026 (TO2) warrants at SEK 0.47 per share, effective today. The company details that 211 warrants are required to subscribe for one new ordinary share, with the exercise period running from 11 September to 2 October 2026. The release emphasizes the mechanical aspects: the total number of outstanding warrants (1,855,541,003), the maximum potential increase in share capital (SEK 2,638,209.90), and the possible rise in ordinary shares (8,794,033) if all warrants are exercised. The narrative is strictly procedural, focusing on key dates, ratios, and instructions for both nominee and directly registered holders. The company does not frame this as a strategic or value-creating event, nor does it provide any operational or financial performance commentary. CEO Joakim Nydemark is listed as the contact, but does not provide additional narrative or forward-looking commentary.

What the data suggests

The subscription price for the warrants is SEK 0.47 per share, calculated as 70% of the average volume-weighted price over the previous ten trading days, capped at SEK 3.20. There are 1,855,541,003 outstanding warrants, and 211 warrants are needed to subscribe for one new share. If all warrants are exercised, the share capital could increase by up to SEK 2,638,209.90 and the number of ordinary shares by up to 8,794,033. The exercise period is immediate, running from 11 September to 2 October 2026, with the last day of trading in the warrants on 30 September 2026. The announcement is complete and specific on the mechanics and potential impact of the warrant exercise, but does not disclose any realised proceeds, operational results, or financial performance metrics. The figures provided are purely structural, with no indication of actual uptake or expected participation.

Analysis

The announcement is a procedural disclosure detailing the terms, timeline, and mechanics of exercising the series 2026 (TO2) warrants for Precise Biometrics AB. All key claims are factual, specific, and supported by numerical data, such as the subscription price (SEK 0.47), exercise period, and maximum potential increase in share capital and shares. The only forward-looking statements are mechanical (e.g., what happens if all warrants are exercised, or the process for registering new shares), and these are standard for such corporate actions. There is no promotional or exaggerated language, no claims of operational or financial improvement, and no attempt to frame the warrant exercise as a strategic or value-creating event. No large capital outlay or long-term benefit is discussed; the process is immediate and routine. The gap between narrative and evidence is nonexistent, as the language is strictly factual.

Risk flags

• ●There is significant dilution risk if a large proportion of the 1,855,541,003 outstanding warrants are exercised, as up to 8,794,033 new shares could be issued, increasing the share count and potentially impacting existing shareholders' ownership percentages.
• ●The announcement does not provide any indication of likely participation rates or investor appetite, so the actual capital raised could be materially lower than the maximum theoretical amount, introducing uncertainty about the net benefit to the company.
• ●No information is provided about the intended use of proceeds or how any funds raised would be deployed, which limits investors' ability to assess the strategic impact or value creation potential of the warrant exercise.

Bottom line

This announcement is a procedural update setting the terms and timeline for exercising Precise Biometrics' series 2026 (TO2) warrants, with a subscription price of SEK 0.47 per share and a tight exercise window. The potential for up to SEK 2,638,209.90 in new share capital and 8,794,033 additional shares exists if all warrants are exercised, but actual participation rates are unknown. No operational or financial performance data is disclosed, and there is no guidance on how any raised funds would be used. The immediate impact will be determined by the level of warrant exercise, with dilution risk for current shareholders if uptake is high. Investors should focus on the exercise rate announcement scheduled for 5 October 2026, as this will reveal the real financial effect. The key takeaway is that this is a routine corporate action with clear mechanics but uncertain financial outcome until exercise results are published.

Announcement summary

(LSE/AIM:0JDU) Precise Biometrics AB announced that the subscription price for the warrants of series 2026 (TO2) has been determined at SEK 0.47 per share. The exercise period for the Warrants begins on 11 September 2026 and ends on 2 October 2026. The last day of trading in the Warrants on Nasdaq Stockholm is 30 September 2026. 211 Warrants entitle the holder to subscribe for one new ordinary share in Precise Biometrics. The subscription price corresponds to 70 percent of the average volume-weighted price for Precise Biometrics share on Nasdaq Stockholm during the ten trading days before, but not including, 11 September 2026, with a maximum of SEK 3.20 per share. The total number of outstanding Warrants amounts to 1,855,541,003. Assuming full exercise of the Warrants, the share capital of Precise Biometrics will increase by a maximum of SEK 2,638,209.90 and the number of ordinary shares will increase by a maximum of 8,794,033. Subscription forms are available on DNB Carnegie’s website and on Precise Biometrics’ website. Warrants not exercised for subscription by 2 October 2026 will expire without value. Subscribed and paid shares will be registered as “interim shares” or “IA” until registration at the Swedish Companies Registration Office, after which they will be converted to shares in Precise Biometrics.

Disagree with this article?